PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors

• Published in: Human pathology 2011-11, Vol.42 (11), p.1710-1719
• Main Authors: Konopka, Bożena, PhD, Janiec–Jankowska, Aneta, PhD, Kwiatkowska, Ewa, MSc, Najmoła, Urszula, MSc, Bidziński, Mariusz, MD, Olszewski, Włodzimierz, MD, Goluda, Cyprian, MD
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Amplification; beta Catenin - genetics; Biological and medical sciences; Carcinoma, Endometrioid - genetics; Carcinoma, Endometrioid - pathology; Class I Phosphatidylinositol 3-Kinases; Endometrial carcinoma; Endometrial Hyperplasia - genetics; Endometrial Neoplasms - genetics; Endometrial Neoplasms - pathology; Enzymes; Female; Female genital diseases; Gene Amplification; Genes, ras - genetics; Gynecology. Andrology. Obstetrics; Humans; Hyperplasia; Investigative techniques, diagnostic techniques (general aspects); Kinases; Medical sciences; Middle Aged; Mutation; Pathology; Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques; Phosphatidylinositol 3-Kinases - genetics; PIK3CA; Polymerase Chain Reaction; Polymorphism, Single-Stranded Conformational; PTEN; PTEN Phosphohydrolase - genetics; Tumors
• ISSN: 0046-8177; 1532-8392
• DOI: 10.1016/j.humpath.2010.01.030

Summary Alterations of the PIK3CA gene occur in endometrial carcinomas, but their role in the carcinogenesis of those malignancies is still poorly understood. In this study, PIK3CA mutations and amplification in 196 endometrioid endometrial carcinomas and 20 endometrial hyperplasias were assessed by single-strand conformation polymorphism (PCR-SSCP), sequencing, and quantitative polymerase chain reaction. Results were correlated with mutations in the PTEN , KRAS , and CTNNB1 genes and with the clinicopathologic parameters of the tumors. PIK3CA mutations were found in 39 (20%) carcinomas. Six new mutations were identified. No PIK3CA mutations were found in endometrial hyperplasias. PIK3CA amplification was observed in 24 (12.2%) carcinomas and in 2 (10%) hyperplasias. The PIK3CA mutations and amplifications (with the exception of 6 cases) occurred independently. PIK3CA mutations were significantly associated with PTEN mutations ( P = .0414) and tended to be associated with CTNNB1 ( P = .0833), but not with KRAS mutations. Conversely, the PIK3CA amplifications significantly negatively correlated with PTEN mutations ( P = .0038) and did not coexist with CTNNB1 and KRAS mutations. The PIK3CA mutations were significantly associated with poorly differentiated tumors ( P = .0423). Interestingly, PIK3CA amplifications, but not mutations, were strongly associated with older age (≥63 years, P = .0018). Our data show that mutations and amplification of PIK3CA are significant genetic alterations in endometrioid endometrial carcinomas associated with adverse clinicopathologic parameters (grade and stage). These data also demonstrate that PIK3CA mutations cooperate with PTEN mutations, suggesting an additive effect to PTEN , whereas PIK3CA amplification can, as an isolated event, enable the development of those tumors. Moreover, for the first time, a possible role of PIK3CA amplification in initiation and progression of endometrial carcinomas in older women is suggested, but this preliminary suggestion requires further research.